Ultragenyx Pharmaceutical Inc. (RARE) Stake Raised by Capital World Investors

Capital World Investors lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 44.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 210,000 shares of the biopharmaceutical company’s stock after buying an additional 65,000 shares during the quarter. Capital World Investors owned approximately 0.49% of Ultragenyx Pharmaceutical worth $13,043,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of RARE. Russell Investments Group Ltd. raised its holdings in shares of Ultragenyx Pharmaceutical by 111.9% in the first quarter. Russell Investments Group Ltd. now owns 27,989 shares of the biopharmaceutical company’s stock worth $1,897,000 after buying an additional 14,780 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Ultragenyx Pharmaceutical by 6.0% in the first quarter. Bank of New York Mellon Corp now owns 185,512 shares of the biopharmaceutical company’s stock worth $12,574,000 after buying an additional 10,450 shares during the period. UBS Asset Management Americas Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 56.1% in the first quarter. UBS Asset Management Americas Inc. now owns 19,841 shares of the biopharmaceutical company’s stock worth $1,345,000 after buying an additional 7,128 shares during the period. Karp Capital Management Corp purchased a new stake in shares of Ultragenyx Pharmaceutical in the first quarter worth approximately $241,000. Finally, Parametric Portfolio Associates LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 34.2% in the first quarter. Parametric Portfolio Associates LLC now owns 32,751 shares of the biopharmaceutical company’s stock worth $2,220,000 after buying an additional 8,353 shares during the period. Hedge funds and other institutional investors own 96.07% of the company’s stock.

RARE has been the topic of several research reports. HC Wainwright restated a “neutral” rating and set a $75.00 price objective (up from $72.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 8th. Jefferies Group LLC restated a “hold” rating and set a $68.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, July 14th. Morgan Stanley restated an “equal weight” rating and set a $71.00 price objective (up from $69.00) on shares of Ultragenyx Pharmaceutical in a report on Friday. Canaccord Genuity reaffirmed a “buy” rating and set a $83.00 target price (down previously from $98.00) on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 22nd. Finally, Evercore ISI began coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, August 16th. They set an “in-line” rating and a $63.00 target price on the stock. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $71.94.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://ledgergazette.com/2017/10/10/ultragenyx-pharmaceutical-inc-rare-stake-raised-by-capital-world-investors.html.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) opened at 53.81 on Tuesday. The firm’s market cap is $2.28 billion. The firm’s 50-day moving average price is $53.58 and its 200-day moving average price is $59.95. Ultragenyx Pharmaceutical Inc. has a 12 month low of $49.56 and a 12 month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.01. During the same quarter last year, the company posted ($1.46) earnings per share. Analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.14) earnings per share for the current year.

In related news, CEO Emil D. Kakkis acquired 7,500 shares of the firm’s stock in a transaction on Monday, August 28th. The stock was bought at an average price of $52.52 per share, for a total transaction of $393,900.00. Following the completion of the purchase, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at approximately $22,613,483.88. The transaction was disclosed in a document filed with the Secu

Several other hedge funds and other institutional investors have also modified their holdings of RARE. Russell Investments Group Ltd. raised its holdings in shares of Ultragenyx Pharmaceutical by 111.9% in the first quarter. Russell Investments Group Ltd. now owns 27,989 shares of the biopharmaceutical company’s stock worth $1,897,000 after buying an additional 14,780 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Ultragenyx Pharmaceutical by 6.0% in the first quarter. Bank of New York Mellon Corp now owns 185,512 shares of the biopharmaceutical company’s stock worth $12,574,000 after buying an additional 10,450 shares during the period. UBS Asset Management Americas Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 56.1% in the first quarter. UBS Asset Management Americas Inc. now owns 19,841 shares of the biopharmaceutical company’s stock worth $1,345,000 after buying an additional 7,128 shares during the period. Karp Capital Management Corp purchased a new stake in shares of Ultragenyx Pharmaceutical in the first quarter worth approximately $241,000. Finally, Parametric Portfolio Associates LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 34.2% in the first quarter. Parametric Portfolio Associates LLC now owns 32,751 shares of the biopharmaceutical company’s stock worth $2,220,000 after buying an additional 8,353 shares during the period. Hedge funds and other institutional investors own 96.07% of the company’s stock.

RARE has been the topic of several research reports. HC Wainwright restated a “neutral” rating and set a $75.00 price objective (up from $72.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 8th. Jefferies Group LLC restated a “hold” rating and set a $68.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, July 14th. Morgan Stanley restated an “equal weight” rating and set a $71.00 price objective (up from $69.00) on shares of Ultragenyx Pharmaceutical in a report on Friday. Canaccord Genuity reaffirmed a “buy” rating and set a $83.00 target price (down previously from $98.00) on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 22nd. Finally, Evercore ISI began coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, August 16th. They set an “in-line” rating and a $63.00 target price on the stock. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $71.94.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://ledgergazette.com/2017/10/10/ultragenyx-pharmaceutical-inc-rare-stake-raised-by-capital-world-investors.html.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) opened at 53.81 on Tuesday. The firm’s market cap is $2.28 billion. The firm’s 50-day moving average price is $53.58 and its 200-day moving average price is $59.95. Ultragenyx Pharmaceutical Inc. has a 12 month low of $49.56 and a 12 month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.01. During the same quarter last year, the company posted ($1.46) earnings per share. Analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.14) earnings per share for the current year.

In related news, CEO Emil D. Kakkis acquired 7,500 shares of the firm’s stock in a transaction on Monday, August 28th. The stock was bought at an average price of $52.52 per share, for a total transaction of $393,900.00. Following the completion of the purchase, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at approximately $22,613,483.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 9.20% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply